Home > Insider Trading > Filing (0000880771-11-000009)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
880771	Sciclone Pharmaceuticals Inc	SCLN	Pharmaceutical Preparations (2834)	943116852

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1328576	D Ira Lawrence	950 Tower Lane, Suite 900 Foster City CA 94404		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-05-20	30,000	$1.75	30,000	No	4	M	Direct
Common Stock	Disposition	2011-05-20	30,000	$5.77	0	No	4	S	Direct
Common Stock	Acquisiton	2011-05-23	30,000	$2.23	30,000	No	4	M	Direct
Common Stock	Disposition	2011-05-23	30,000	$5.77	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-05-20	30,000	$5.77	30,000	$1.75
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-05-23	30,000	$5.77	30,000	$2.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2018-06-10	No	4	M	Direct
0		2019-06-09	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.76 to $5.7947.
The price reported in Column 4 is a weighted average price. These share were sold in multiple transactions at prices ranging from $5.74 to$5.79
Granted under the Issuer's 2004 Outside Directors Stock Option Plan.
Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer.